Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

Goldman Sachs analyst Chris Shibutani adjusted the price target for Merck (NSE:PROR) & Co. Inc. (NYSE:MRK) to $129.00, down from the previous $135.00, while reiterating a Buy rating on the ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Case Closed Movie: The Time Bombed Skyscraper (movie 1): Art Director Case Closed: Captured in Her Eyes (movie 4): Art Director Case Closed: Countdown to Heaven (movie 5): Art Director Case Closed ...

Chris Shibutani is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future ...

See the 10 stocks » The first came from white-shoe investment bank Goldman Sachs, whose analyst Chris Shibutani bumped his fair value assessment to $208 per share from the previous $205.